

Status: Currently Official on 15-Feb-2025
Official Date: Official as of 01-May-2022
Document Type: USP Monographs
DocId: GUID-9754BF50-7C90-45D6-A74F-C45DE04A27D8_2_en-US
DOI: https://doi.org/10.31003/USPNF_M47898_02_01
DOI Ref: i6i2d

© 2025 USPC
Do not distribute

Meclofenamate Sodium Capsules

DEFINITION

Meclofenamate Sodium Capsules contain an amount of meclofenamate sodium ($C_{14}H_{10}Cl_2NNaO_2$) equivalent to NLT 90.0% and NMT 110.0% of the labeled amount of meclofenamic acid ($C_{14}H_{11}Cl_2NO_2$).

IDENTIFICATION

Delete the following:

▲ • [THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST \(201\)](#).

Sample solution: 20 mg/mL of meclofenamate sodium, from Capsule contents in methanol; filter

Developing solvent system: [Methylene chloride](#), [methyl ethyl ketone](#), and [glacial acetic acid](#) (50:48:2)

Acceptance criteria: The filtrate meets the requirements.▲ (USP 1-May-2022)

Add the following:

▲ • **A.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.▲ (USP 1-May-2022)

Add the following:

▲ • **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.▲ (USP 1-May-2022)

ASSAY

Change to read:

• **PROCEDURE**

▲ **Solution A:** 0.63 g/L of [ammonium formate](#) in [water](#). Adjust with [formic acid](#) to a pH of 3.0.

Solution B: [Acetonitrile](#)

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	30	70
1	30	70
12	5	95
13	5	95
14	30	70
18	30	70

Diluent: [Methanol](#) and [water](#) (50:50)

Standard solution: 0.3 mg/mL of [USP Meclofenamate Sodium RS](#) in *Diluent*

Sample solution: Nominally 0.28 mg/mL of meclofenamic acid, equivalent to 0.3 mg/mL of meclofenamate sodium (anhydrous) in *Diluent*, prepared as follows. Mix the contents of Capsules (NLT 10) and transfer a suitable portion to a suitable volumetric flask. Add *Diluent* to about 80% of the volume, vortex, and sonicate for NLT 5 min. Dilute with *Diluent* to volume. Pass through a suitable filter of 0.45-µm pore size and use the filtrate.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 270 nm. For *Identification B*, use a diode array detector in the range of 190–400 nm.

Column: 4.6-mm × 15-cm; 3.5-μm packing [L1](#)

Column temperature: 35°

Flow rate: 0.8 mL/min

Injection volume: 10 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of meclofenamic acid ($C_{14}H_{11}Cl_2NO_2$) in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of meclofenamate from the *Sample solution*

r_S = peak response of meclofenamate from the *Standard solution*

C_S = concentration of [USP Meclofenamate Sodium RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of meclofenamic acid in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of meclofenamic acid, 296.15

M_{r2} = molecular weight of meclofenamate sodium (anhydrous), 318.13▲ (USP 1-May-2022)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

- [DISSOLUTION \(711\)](#)

Medium: 0.05 M pH 7.5 phosphate buffer (See [Reagents, Indicators, and Solutions, Solutions, Buffer Solutions](#)); 900 mL

Apparatus 2: 50 rpm

Time: 45 min

Standard solution: A known concentration of [USP Meclofenamate Sodium RS](#) in *Medium*

Sample solution: Pass a portion of the solution under test through a suitable filter. Dilute with *Medium*, if necessary.

Instrumental conditions

Analytical wavelength: 279 nm (maximum absorbance)

Mode: UV

▲ Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of meclofenamic acid ($C_{14}H_{11}Cl_2NO_2$) dissolved:

$$\text{Result} = (A_U/A_S) \times C_S \times V \times D \times (1/L) \times (M_{r1}/M_{r2}) \times 100$$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of [USP Meclofenamate Sodium RS](#) in the *Standard solution* (mg/mL)

V = volume of *Medium*, 900 mL

D = dilution factor of the *Sample solution* if needed

L = label claim (mg/Capsule)

M_{r1} = molecular weight of meclofenamic acid, 296.15

M_{r2} = molecular weight of meclofenamate sodium (anhydrous), 318.13▲ (USP 1-May-2022)

Tolerances: NLT 75% (Q) of the labeled amount of meclofenamic acid ($C_{14}H_{11}Cl_2NO_2$) is dissolved.

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

IMPURITIES

Add the following:

▲ • ORGANIC IMPURITIES

Solution A, Mobile phase, Diluent, Sample solution, and Chromatographic system: Proceed as directed in the Assay.

Standard solution: 0.6 µg/mL of [USP Meclofenamate Sodium RS](#) in *Diluent*

Sensitivity solution: 0.3 µg/mL of [USP Meclofenamate Sodium RS](#) in *Diluent* from *Standard solution*

System suitability

Samples: *Standard solution* and *Sensitivity solution*

Suitability requirements

Tailing factor: NMT 2.0, *Standard solution*

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Sample solution* and *Standard solution*

Calculate the percentage of any degradation product in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

r_U = peak response of any degradation product from the *Sample solution*

r_S = peak response of meclofenamate from the *Standard solution*

C_S = concentration of [USP Meclofenamate Sodium RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of meclofenamic acid in the *Sample solution* (mg/mL)

M_{r1} = molecular weight of meclofenamic acid, 296.15

M_{r2} = molecular weight of meclofenamate sodium (anhydrous), 318.13

Acceptance criteria: See [Table 2](#). The reporting threshold is 0.1%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Meclofenamate	1.0	—
Any degradation product	—	0.2
Total degradation products	—	1.0

▲ (USP 1-May-2022)

ADDITIONAL REQUIREMENTS

Change to read:

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers ▲ at controlled room temperature. ▲ (USP 1-May-2022)
- **USP REFERENCE STANDARDS (11).**
[USP Meclofenamate Sodium RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MECLOFENAMATE SODIUM CAPSULES	Documentary Standards Support	SM22020 Small Molecules 2

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 46(4)

Current DocID: GUID-9754BF50-7C90-45D6-A74F-C45DE04A27D8_2_en-US

DOI: https://doi.org/10.31003/USPNF_M47898_02_01

DOI ref: [i6i2d](#)

OFFICIAL